Reports of seven deaths in patients who had taken Neurocrine Biosciences’ Vykat and the official termination of Aardvark Therapeutics’ Phase 3 trial after cardiac complications marked a tough day for the Prader-Willi syndrome community.
Deaths reported after treatment with Neurocrine’s approved Prader-Willi drug Read More »
Philips framed the revised agreement with Exor, the holding company of Italy’s billionaire Agnelli family, as evidence of confidence in its strategy.
Philips authorizes largest shareholder to increase stake to 22% Read More »
It’s smooth sailing for Definium Therapeutics as the psychedelic biotech charts another win for its LSD candidate, this time in anxiety. The psychedelic previously notched a late-stage victory in depression.
Definium’s LSD asset beats analyst expectations in Phase 3 anxiety readout Read More »
The multiyear partnership will connect Abbott’s over-the-counter Lingo sensor and the Google Health app.
Abbott, Google to combine glucose data with AI coaching Read More »
The company says its patient portal should help translate medical jargon into plain language. It’s Oracle’s latest move to stand out in the competitive EHR market.
Looking for a biopharma job in North Carolina? Job postings in the area have increased. Here are seven companies with open roles.
Beyond the legal action, Eli Lilly is calling on healthcare providers, regulatory authorities, online platforms and even logistics companies to help stem the illegal sale of its next-generation asset for weight loss.
Lilly cracks down on black market for obesity asset retatrutide with six lawsuits Read More »
The libertarian think tank analyzed almost 130 studies digging into the controversial laws, which require providers to get state approval before building facilities or adding new services. What it found wasn’t good.
New Cato report excoriates certificate of need laws Read More »
BridgeBio Pharma’s transthyretin amyloidosis medicine Attruby is off to a strong launch, while Alnylam lowered full-year sales guidance for competitor Amvuttra.
BridgeBio continues ATTR ascent as Alnylam’s Amvuttra falls short of expectations Read More »
Mereo BioPharma’s asset, dubbed alvelestat, is set to enter Phase 3 development for AATD-LD in 2027.
Sentynl bets up to $475M in licensing deal for Mereo’s rare lung disease asset Read More »
